Table 3

Frequencies of response among subjects to the candidate glioma-associated T helper cell epitopes
MAGE-A3112-127 MAGE-A3121-136 MAGE-A3143-160 IL-13Rα2341-355 IL-13Rα2351-365
Primary GBM 1 ++ ++++ + +++
Primary GBM 2 ++ ++ +++ ++ ++
Primary GBM 3 ++ ++++ + +++++ ++
Primary GBM 4 + ++ + +++
Primary GBM 5 +++++ ++++ + ++ +
Primary GBM 6 ++ ++ + ++
Primary GBM 7 +++ ++++ ++ +++ +++
Primary GBM 8 ++++ ++ +++++ ++++ +++++
Recurrent GBM 1 + ++ + ++ ++
Recurrent GBM 2 +
Recurrent GBM 3 ++ + + +
Recurrent GBM 4 ++ + +
Recurrent GBM 5 + + ++
Meningioma 1 +
Meningioma 2 +++
Meningioma 3 +
Meningioma 4 +
Meningioma 5 +++ ++ ++
Meningioma 6 + + + + ++++++
Meningioma 7 +
Healthy Subject 1 +++ +++ +++ +
Healthy Subject 2 + +++ +
Healthy Subject 3 ++ +++ +
Healthy Subject 4 ++ + +++++ + +++++
Healthy Subject 5 + + ++ ++++ ++
Healthy Subject 6 + + + ++

Cytokine production was quantified by ELISA, defining a positive T cell response for each patient as the amounts of IFN-γ or IL-5 that were > 50 pg/mL and two standard deviations above the mean cytokine levels secreted after stimulation of cells from that patient with negative control MBP peptide. A total of 6 primary T cell responses were measured for each subject against each peptide. (+) symbols indicate the precise number of positive wells among six for each peptide.

Shimato et al.

Shimato et al. BMC Cancer 2012 12:561   doi:10.1186/1471-2407-12-561

Open Data